1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Competitor Analysis: Interferon

Competitor Analysis: Interferon

  • April 2013
  • -
  • La Merie Publishing
  • -
  • 89 pages

Product description

The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural interferon alpha, beta, gamma, lambda and of other subtypes for treatment of hepatitis B and C, other infectious diseases, cancer and multiple sclerosis, respectively. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report provides information on the marketed interferon preparations and includes a compilation of current active projects in research and development of novel interferon products including novel presentation or delivery formats. In addition, the report lists company-specific product portfolios and R&D pipelines of interferon products and projects. Competitor projects are listed in a tabular format providing information on:
• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Interferon
Table of Contents

1. Interferon alpha, beta and other sub-types

a) INTERFERON alpha
Interferon alpha sales 2012 of branded products in regulated markets
1st generation Interferon alpha-2a in regulated markets
1st generation Interferon alpha-2a in non-regulated markets
Next generation Interferon alpha-2a in regulated markets
Next generation Interferon alpha-2a in non-regulated markets and biosimilars
1st generation Interferon alpha-2b in regulated markets
1st generation Interferon alpha-2b in non-regulated markets and biosimilars
Next generation Interferon alpha-2b in regulated markets
Next generation Interferon alpha-2b in non-regulated markets and biosimilars
Other Interferon alpha sub-types
Interferon alpha with not specified sub-type - 1/2
Purified natural human interferon alpha

b) Consensus INTERFERONs

c) INTERFERON beta
Interferon beta sales 2012 of branded products in regulated markets
1st generation Interferon beta-1a in regulated markets
1st generation Interferon beta-1a in non-regulated markets and biosimilars
1st generation Interferon beta-1b in regulated markets
1st generation Interferon beta-1b in non-regulated markets and biosimilars
1st generation Interferon beta with not disclosed sub-type
Next generation Interferon beta in regulated markets
Purified natural human interferon beta

d) INTERFERON gamma

e) Other INTERFERONs

2. Corporate Interferon Product Portfolios and RandD Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase ...

Protein Labeling Market by Product, Labeling Method, Application, & Region - Global Forecast to 2020

Protein Labeling Market by Product, Labeling Method, Application, & Region - Global Forecast to 2020

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global protein labeling market is expected to reach USD 1,894.5 million by 2020 from USD 1,089.5 million in 2015, at a CAGR of 11.7% from 2015 to 2020. On the basis of products, the protein labeling ...

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.